These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7591543)

  • 21. [Patient education and specialty prescription information from the psychiatric viewpoint].
    Linden M
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):662-7; discussion 667-8. PubMed ID: 9527465
    [No Abstract]   [Full Text] [Related]  

  • 22. [Drug control within the EEC II: good possibilities for Sweden].
    Strandberg K
    Lakartidningen; 1992 Jan; 89(4):178-9. PubMed ID: 1734147
    [No Abstract]   [Full Text] [Related]  

  • 23. Assessment of prescribing information for generic drugs manufactured in the Middle East and marketed in Saudi Arabia.
    Gebran N; Al Haidari K
    Ann Saudi Med; 2006; 26(3):192-9. PubMed ID: 16861873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug marketing: nonfederal regulation.
    Skinner WJ
    Hosp Formul; 1978 Nov; 13(11):911-2, 915-6, 918. PubMed ID: 10239345
    [No Abstract]   [Full Text] [Related]  

  • 25. Information or advertising?
    Coulter A
    Health Expect; 2001 Dec; 4(4):203-4. PubMed ID: 11703492
    [No Abstract]   [Full Text] [Related]  

  • 26. Medication information for patients with limited English proficiency: lessons from the European Union.
    Regenstein M; Andres E; Nelson D; David S; Lopert R; Katz R
    J Law Med Ethics; 2012; 40(4):1025-33. PubMed ID: 23289703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Data sheets: a consumer perspective.
    Medawar C
    Lancet; 1988 Apr; 1(8588):777-8. PubMed ID: 2895311
    [No Abstract]   [Full Text] [Related]  

  • 28. [Patient education responsibility, specialty and administration information from the internal medicine viewpoint].
    Ludwig WD
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):657-61. PubMed ID: 9527464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Packaging of pharmaceuticals: still too many dangers but several encouraging initiatives.
    Prescrire Int; 2007 Jun; 16(89):126-8. PubMed ID: 17585428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A short history of patient package insert in the EU].
    Oshima K
    Yakushigaku Zasshi; 1995; 30(2):164-72. PubMed ID: 11613533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient package inserts: the proper prescription?
    Rowe HM
    Food Drug Law J; 1995; 50(1):95-124. PubMed ID: 10342988
    [No Abstract]   [Full Text] [Related]  

  • 32. [Use of antidepressants during breastfeeding: evaluating drug package inserts conformity with science-based bibliographical sources].
    Pizzol TDSD; Moraes CG; Diello MV; Campos PM; Pletsch JT; Giugliani C
    Cad Saude Publica; 2019 Feb; 35(2):e00041018. PubMed ID: 30785486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient information leaflets on over-the-counter (OTC) medicines: the manufacturer's perspective.
    Bradley B; McCusker E; Scott E; Li Wan Po A
    J Clin Pharm Ther; 1995 Feb; 20(1):37-40. PubMed ID: 7775612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Drug package inserts and the adequacy of patient's drug information].
    da Silva T; Dal-Pizzol F; Bello CM; Mengue SS; Schenkel EP
    Rev Saude Publica; 2000 Apr; 34(2):184-9. PubMed ID: 10881155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short communication: a study on the packaging information of essential drug products used at Union and Thana health complex level in Bangladesh.
    Amran S; Ahmed M; Shaheen SM; Morshed SN; Khandakar J; Rahman M; Rahman M; Hossain A
    Pak J Pharm Sci; 2007 Oct; 20(4):327-32. PubMed ID: 17604258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory agencies' recommendations for medicine information leaflets: Are they in line with research findings?
    Young A; Tordoff J; Smith A
    Res Social Adm Pharm; 2018 Feb; 14(2):196-202. PubMed ID: 28285793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Presentation and distribution of medicinal products after the new E.U. marketing procedures.
    Montanari L; Minghetti P; Giudici EM
    Pharmacol Res; 1997 Jan; 35(1):37-42. PubMed ID: 9149314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [More than 1 out of 100 will have myocardial infarction and stroke because of enalapril--effect of drug package inserts?].
    Sandström H
    Lakartidningen; 2006 Feb 22-28; 103(8):564, 567; discussion 567. PubMed ID: 16570783
    [No Abstract]   [Full Text] [Related]  

  • 39. Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports.
    Köhler M; Haag S; Biester K; Brockhaus AC; McGauran N; Grouven U; Kölsch H; Seay U; Hörn H; Moritz G; Staeck K; Wieseler B
    BMJ; 2015 Feb; 350():h796. PubMed ID: 25722024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cisapride and patient information leaflets.
    Sukkari SR; Sasich LD
    CMAJ; 2001 May; 164(9):1276-8; author reply 1278-9. PubMed ID: 11341134
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.